Development and Validation of a New Analytical Method for the Determination of Related Components and Assay of Ranolazine in Bulk Drug and Pharmaceutical Dosage Forms by LC
Authors:
- 26 May 2009
- journal article
- Published by Springer Nature in Chromatographia
- Vol. 70 (1-2) , 333-338
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Determination of ranolazine in human plasma by LC–MS/MS and its application in bioequivalence studyJournal of Pharmaceutical and Biomedical Analysis, 2008
- Effects of Ranolazine on Recurrent Cardiovascular Events in Patients With Non–ST-Elevation Acute Coronary SyndromesThe MERLIN-TIMI 36 Randomized TrialJAMA, 2007
- Sensitive quantification of ranolazine in human plasma by liquid chromatography–tandem mass spectrometry with positive electrospray ionizationJournal of Chromatography B, 2007
- Ranolazine, an Inhibitor of the Late Sodium Channel Current, Reduces Postischemic Myocardial Dysfunction in the RabbitJournal of Cardiovascular Pharmacology and Therapeutics, 2006
- Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat heartsJournal of Molecular and Cellular Cardiology, 2006
- Antianginal Efficacy of Ranolazine When Added to Treatment With AmlodipineJACC, 2006
- Stress degradation studies on ezetimibe and development of a validated stability-indicating HPLC assayJournal of Pharmaceutical and Biomedical Analysis, 2006
- Effects of Ranolazine With Atenolol, Amlodipine, or Diltiazem on Exercise Tolerance and Angina Frequency in Patients With Severe Chronic AnginaA Randomized Controlled TrialJAMA, 2004
- Development of validated stability-indicating assay methods—critical reviewJournal of Pharmaceutical and Biomedical Analysis, 2002
- Estimation of ranolazine and eleven Phase I metabolites in human plasma by liquid chromatography-atmospheric pressure chemical ionisation mass spectrometry with selected-ion monitoringJournal of Chromatography A, 1995